• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cilostazol for the Prevention of Acute Progressing Stroke: A Multicenter, Randomized Controlled Trial
Conclusions: Cilostazol failed to show a preventive effect against acute progressing stroke. However, the tendency to reduce progressing stroke and the results of stratified analyses may encourage additional studies to clarify the effect of cilostazol in the treatment of acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Hiroaki Shimizu, Teiji Tominaga, Akira Ogawa, Takamasa Kayama, Kazuo Mizoi, Kiyoshi Saito, Yasuo Terayama, Kuniaki Ogasawara, Etsuro Mori, Tohoku Acute Stroke Progressing Stroke Study Group Tags: Original Articles Source Type: research

Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study
Atherosclerosis is one of the main mechanisms of stroke and cardiovascular diseases and is associated with increased risk of recurrent stroke and cardiovascular events. Intima-medial thickness (IMT) is a well-known surrogate marker of atherosclerosis and has been used to predict stroke and cardiovascular events. However, the clinical significance of IMT and IMT change in stroke has not been investigated in well-designed studies. The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage —Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of...
Source: Journal of Stroke and Cerebrovascular Diseases - July 21, 2017 Category: Neurology Authors: Woo-Keun Seo, Yong Jae Kim, Juneyoung Lee, Sun U. Kwon, PICASSO Investigators Source Type: research

Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage
Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function.
Source: Journal of Stroke and Cerebrovascular Diseases - May 31, 2016 Category: Neurology Authors: Kyung-Ho Yu, Keun-Sik Hong, Mi-Sun Oh, Juneyoung Lee, Ji Sung Lee, Sun U. Kwon, PICASSO investigators Source Type: research

Antiplatelet Therapy as a Risk Factor for Microbleeds in Intracerebral Hemorrhage Patients: Analysis Using Specific Antiplatelet Agents
Conclusions: Attention to microbleed-positive patients is necessary for the safe use of aspirin in order to avoid antiplatelet-associated hemorrhages, but prospective studies are needed to verify our results.
Source: Journal of Stroke and Cerebrovascular Diseases - July 12, 2012 Category: Neurology Authors: Hiromitsu Naka, Eiichi Nomura, Jyuri Kitamura, Eiji Imamura, Shinichi Wakabayashi, Masayasu Matsumoto Tags: Original Articles Source Type: research

Prospective Registry of Carotid Artery Stenting in Japan—Investigation on Device and Antiplatelet for Carotid Artery Stenting
Background: Carotid artery stenting (CAS) is minimally invasive but may cause perioperative cerebral infarction associated with distal embolization. We conducted a multicenter prospective observational study on the onset of vascular events after CAS to find out the efficacy and safety of CAS in Japan and to investigate the effects of antiplatelet drugs administered before and after CAS on efficacy and safety of CAS.Methods: A total of 949 patients with cervical carotid artery stenosis were enrolled at 43 institutions in Japan; 934 who had undergone CAS with antiplatelet drugs and followed for 1 year were analyzed. Primary ...
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Nobuyuki Sakai, Hiroshi Yamagami, Yoshihiro Matsubara, Masayuki Ezura, Akio Hyodo, Yuji Matsumaru, Shigeru Miyachi, Yasushi Okada, Tomoaki Terada, Hiroyoshi Yokoi, Mitusugu Nakamura, Yasushi Matsumoto, Chiaki Sakai, IDEALCAST Investigators Tags: Original Articles Source Type: research

Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research

Carotid Plaque Characteristics on Magnetic Resonance Plaque Imaging Following Long-term Cilostazol Therapy
Conclusions: Signal alterations on MR plaque imaging indicated the increase of fibrous components and the decrease of lipid/necrotic components in the carotid plaque during the cilostazol therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - August 29, 2014 Category: Neurology Authors: Mao Yamaguchi Oura, Makoto Sasaki, Hideki Ohba, Shinsuke Narumi, Kazumasa Oura, Ikuko Uwano, Yasuo Terayama Tags: Original Articles Source Type: research

Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis
Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects. We aimed to analyze the effects of cilostazol on symptomatic vasospasm and clinical outcome among patients with aneurysmal subarachnoid hemorrhage (aSAH).
Source: Journal of Stroke and Cerebrovascular Diseases - August 6, 2018 Category: Neurology Authors: Hamidreza Saber, Aaron Desai, Mohan Palla, Wazim Mohamed, Navid Seraji-Bozorgzad, Muhammed Ibrahim Source Type: research